TY - JOUR T1 - Cholesterol Metabolism—Impacts on SARS-CoV-2 Infection Prognosis JF - medRxiv DO - 10.1101/2020.04.16.20068528 SP - 2020.04.16.20068528 AU - Yumeng Peng AU - Luming Wan AU - Chen Fan AU - Pingping Zhang AU - Xiaolin Wang AU - Jin Sun AU - Yanhong Zhang AU - Qiulin Yan AU - Jing Gong AU - Huan Yang AU - Xiaopan Yang AU - Huilong Li AU - Yufei Wang AU - Yulong Zong AU - Feng Yin AU - Xiaoli Yang AU - Hui Zhong AU - Yuan Cao AU - Congwen Wei Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/13/2020.04.16.20068528.abstract N2 - In this study, we specifically addressed the connection between the SARS-CoV-2 virus with host cholesterol metabolism. Plasma lipid profile was measured in 861 COVID-19 patients classified as mild (n=215), moderate (n=364), severe (n=217) or critical (n=65) and 1108 age- and sex-matched healthy individuals. We showed that the levels of both TG and HDL-C were significantly lower in patients with severe disease than in patients with moderate or mild disease. After successful treatment, cholesterol metabolism was reestablished in patients with SARS-CoV-2 infection. The serum concentrations of TC and HDL-C can be used as indicators of disease severity and prognosis in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a single center based retrospective study, not a clinical trial.Funding StatementThis work is funded by the National Natural Science Foundation of China (No.81572620) and Shandong Provincial Natural Science Foundation of China (No.ZR2015HM003)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, or code generated or used during the study are available from the corresponding author by request. ER -